NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

计划入组 20 人 · 首次发布于 2023 年 8 月 9 日

AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)

计划入组 37 人 · 首次发布于 2020 年 2 月 17 日

AAV Gene Therapy Study for Subjects with PKU

计划入组 100 人 · 首次发布于 2020 年 7 月 21 日

gene therapy (Targeted Genetics (Genovo))

AAV9-HEXA/HEXB gene therapy (Axovant Sciences)

AAV-based ABCA4 gene therapy (Biogen)

CELL AND GENE THERAPY CATAPULT

United Kingdom

Asklepios Biopharmaceutical, Inc.

United States

Abeona Therapeutics

United States

Siren Biotechnology Partners with Catalent to Advance AAV Immuno-Gene Therapies for Cancer

Siren Biotechnology's SRN-101 Receives FDA Designations for High-Grade Gliomas

Siren Biotechnology Unveils Promising Preclinical Data for Novel Cancer Treatment Combining AAV Gene Therapy with Cytokine Immunotherapy